OTS - R-Biopharm acquires Australian lab equipment manufacturer and molecular biology multiplex specialist AusDiagnostics
2022. June 07. 10:00
Darmstadt, Germany, June 7, 2022(APA/OTS) - Gaining new market
segments in clinical diagnostics - globally unique position as
system supplier in laboratory diagnostics sector - R-Biopharm AG, a
leading German biotechnology company operating on a global scale,
announced the acquisition of AusDiagnostics. R-Biopharm is
expanding its product portfolio with the addition of the Australian
specialist and manufacturer of molecular biology multiplex
diagnostics, extraction reagents, and laboratory automation
equipment. The company is thereby unlocking new market segments in
clinical diagnostics and continuing on its path of steady
internationalization. "The existing and future molecular biology
multiplex analysis platforms for syndrome testing from system
supplier AusDiagnostics broadens our molecular biology expertise
and perfectly complements our present clinical diagnostics
portfolio," states Christian Dreher, CEO of R-Biopharm. "The
acquisition strengthens our position as a reliable partner for
system solutions and offers our customers additional options for
diagnostics."
- Picture is available at AP Images (http://www.apimages.com) -
Upon its establishment in 2006, the Australian company
introduced its patented Multiplex Tandem PCR (MT-PCR) on the
market. The current technology allows the simultaneous detection of
up to 24 pathogens or resistance genes from a single sample, thus
shortening the lengthy test procedure in human and animal
diagnostics as well as environmental, agricultural, and food
analysis. The analysis platform is used in laboratories and
hospitals throughout the world for detecting a broad range of
diseases.
AusDiagnostics CEO Scott Gilroy said that the transaction
marked an exciting new chapter for the company: "Both
AusDiagnostics and R-Biopharm AG share the same commitment to
innovation in the biotechnology space. This acquisition strengthens
AusDiagnostics and will accelerate our global presence. We've
experienced tremendous, industry-leading growth over the past two
years, which has been underpinned by our broad suite of innovative
products, talented team, and incredible, loyal customers. Joining
the R-Biopharm group will allow us to further build on this and
continue to deliver exceptional products and service for our
Australian and international customers."
AusDiagnostics currently has 92 employees with offices in New
Zealand, the USA, and Great Britain. Its production facilities in
Australia and Great Britain supply a steadily growing network of
more than 25 distributors and partners around the world - from
which R-Biopharm expects further synergy effects for production as
well as international service and support in its clinical
diagnostics line.
About R-Biopharm
R-Biopharm AG, located in Darmstadt, is one of Germany's
leading biotechnology companies. It considers itself as a pioneer
for health and quality of life. The company´s aspiration is to
provide the highest possible precision, safety, clarity and
certainty with excellent products and solutions - in prevention,
therapy and healing. Research and development at R-Biopharm has
developed agile processes in order to take on new challenges to
accompany a steadily growing world population into a new health era
with sustainable solutions.
As an internationally recognized leader, R-Biopharm stands for
the development of excellent technologies, products and solutions
in the fields of Clinical Diagnostics, Nutrition Care and Food and
Feed Analytics. R-Biopharm is the global market leader for test
systems in the field of allergen analysis. The biotechnology
company is known for its products that are of high importance for
human health. To this end, it unites development, production and
sales under one roof and is successfully represented in more than
120 countries worldwide - through 28 subsidiaries and 120
distributors. Founded in 1988, the family-run company employs a
total of around 1,300 people worldwide (690 at its headquarters in
Darmstadt) and was repeatedly recognized with the "Sustainability
Award" for sustainable and profitable growth. R-Biopharm is
cultivating a value-oriented corporate culture and management and
is family-run in the second generation. The Chairman of the Board
of Directors is Christian Dreher.
Press contact:
Simone Feiler
Head of Corporate Brand Communication
https://r-biopharm.com/
https://r-biopharm.com/news-press/download-gallery/
R-Biopharm AG
An der neuen Bergstraße 17
64297 Darmstadt, Germany
Tel.: +49 61 51 - 81 02-538
Mobile: +49 160 - 55 273 60
Fax: +49 61 51 - 81 02-40
Email: s.feiler@r-biopharm.de
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók a
forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI által
szó szerint továbbított tartalomért minden esetben a beadó a
felelős.
© Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.